# Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

> **NCT03236129** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 52 (estimated)

## Conditions studied

- Hematological Malignancies
- Regulatory T Cell Depletion
- Relapse

## Interventions

- **PROCEDURE:** T-reg depleted DLI
- **PROCEDURE:** Standard DLI

## Key facts

- **NCT ID:** NCT03236129
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-22
- **Primary completion:** 2025-02
- **Final completion:** 2026-02
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236129, "Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03236129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*